Background: Eradication rates of Helicobacter pylori with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. Aim: To assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection. Methods: One thousand and forty-nine dyspeptic patients were studied prospectively. H. pylori-infected patients were randomized to receive 10-day sequential therapy [rabeprazole (40 mg daily) plus amoxicillin (1 g twice daily) for the first 5 days, followed by rabeprazole (20 mg), clarithromycin (500 mg) and tinidazole (500 mg) twice daily for the remaining 5 days]
INTRODUCTION
Helicobacter pylori is a human pathogen that causes chronic gastritis and gastric and duodenal ulcers and has been recognized as a class I gastric carcinogen. 1 The ideal antimicrobial therapy should have an eradication rate of at least 90%, a low incidence of significant side-effects and should be available world-wide. The European Helicobacter pylori Study Group guidelines advocate a proton pump inhibitor plus two antibiotics (clarithromycin or metronidazole in combination with amoxicillin) for 1 week as first-line therapy, and an international world-wide panel of experts has also recently endorsed this regimen. 2 The guidelines of the American College of Gastroenterology recommend therapy with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole, or an alternative combination of ranitidine bismuth citrate with clarithromycin or amoxicillin in combination with metronidazole or tetracycline, for 2 weeks. 3 However, recent studies have shown disappointing results with these regimens. A meta-analysis performed by Janssen et al. showed a pooled intention-to-treat eradication rate of 79% for proton pump inhibitor triple therapies using either amoxicillin [95% confidence interval (CI), or nitroimidazole (95% CI, 33-100). 4 Even lower eradication rates, ranging from 60% to 75%, have been reported in several countries, such as Italy, France, Ireland, Belgium, Japan, China, Brazil and South Africa. [5] [6] [7] [8] [9] [10] [11] It has been suggested that prolonging proton pump inhibitor-based triple therapy beyond 7 days may improve the eradication rate. Nevertheless, Calvet et al., in a meta-analysis, showed only a modest improvement when 14-day therapies were compared with 7-day treatments (odds ratio in favour of 14 days of treatment, 0.62; 95% CI, 0.45-0.84). 12 Antimicrobialresistant strains of H. pylori have been increasing in the USA and Europe, and this may account for the decreasing eradication rates reported. 13, 14 Thus, the optimal eradication treatment is still a matter of debate, and new therapeutic approaches are necessary. Recently, a novel sequential treatment regimen has been reported to have high success rates in pilot studies. 15, 16 Therefore, the main objective of this study was to assess the eradication rate of this new sequential therapeutic regimen in a large, multi-centre, randomized controlled trial compared with standard 7-day triple therapy.
MATERIALS AND METHODS

Patients
This open-label, randomized controlled trial involved eight Italian clinical centres (Rome, Bologna, Foggia, San Giovanni Rotondo, Lecce, Piacenza and Mantova) and was conducted between January 2001 and December 2001. Determination of whether a patient would be treated by new or standard therapy was made by reference to a computer-generated randomization list drawn up for each centre by a statistician. The details of the series were unknown to any of the investigators or the co-ordinator, and were contained in a set of opaque, sealed envelopes, each bearing on the outside only the name of the hospital and a number; they were sent to each centre. After the patient had given informed consent to participate in the study, the appropriate numbered envelope was opened in each centre; the card inside indicated whether the patient was to be treated by new or standard therapy. This procedure was chosen to separate the creation of the allocation sequence from the assignment to the study group in order to avoid bias. 17 The study population consisted of patients with dyspepsia (defined as pain or discomfort centred in the upper abdomen 18 ), who were referred by primary care physicians for upper endoscopy. Consenting patients were enrolled if they were infected with H. pylori, according to the guidelines for clinical trials in H. pylori infection. 19 Patients enrolled in the present study were not enrolled in other studies, and had not been treated previously for H. pylori infection. Patients were excluded if they had taken proton pump inhibitors, H 2 -receptor antagonists or antibiotics in the 4 weeks preceding the study. Pregnant women, patients with known antibiotic allergy and those with hepatic impairment or kidney failure were not enrolled. At baseline, patients underwent endoscopy, with biopsies taken for histology (two samples from the antrum and two samples from the corpus) and a rapid urease test (one sample from the antrum) (CP-test, Yamamouchi, Milan, Italy). Two biopsy samples (one from the antrum and one from the corpus) were collected to perform bacterial culture and susceptibility testing in one centre only. For the purposes of this study, peptic ulcer was defined as a mucosal ulcer of > 5 mm in diameter. Within 24 h of endoscopy, patients completed a urea breath test. Breath tests were carried out after an overnight fast. Citric acid (1.5 g) as test meal and 75 mg of 13 C-urea as water solution were given to the patients after collection of a baseline sample, obtained by blowing through a disposable plastic straw into a 20-mL container; the test sample was collected 30 min later. The breath samples were analysed by a gas isotope ratio mass spectrometer and were considered to be positive if there was a greater than 5& 13 CO 2 difference over baseline, according to the manufacturer's recommendations. At baseline, patients were considered to be H. pylori positive if two out of three tests (histology, rapid urease test, 13 C-urea breath test) were positive. All other combinations were considered to be negative for infection. Patients were considered to have successful eradication at follow-up if all three tests were negative. These criteria have been recommended by an expert panel for use in clinical trials of H. pylori eradication. 19 The ethics committee of S. Orsola Hospital, Bologna, Italy approved the protocol for all eight Italian clinical centres and all participants gave written informed consent.
Histology, bacterial culture and susceptibility testing
Histological biopsies were stained with haematoxylin and eosin plus Giemsa stains, and gastritis was scored using the updated Sydney system. 20 Biopsies collected for bacterial culture were streaked on to Columbia agar enriched with 5% horse blood and containing vancomycin, trimethoprim, polymixin B and nalidixic acid to inhibit the grow of microbes other than H. pylori. The plates were incubated in a micro-aerobic environment at 37°C for 7 days, and inspected daily from the third day. The isolates were identified by Gram stain and by oxidase, catalase and urease tests. The E-test (AB Biodisk, Solna, Sweden) was performed according to the manufacturer's guidelines. All susceptibility testing was carried out on Mueller-Hinton agar with 5% aged sheep blood ( ‡ 2 weeks old) (freshly prepared). Isolates were considered to be resistant to nitroimidazole, clarithromycin and amoxicillin if minimal inhibitory concentrations were ‡ 8 lg/mL, ‡ 1 lg/mL and ‡ 0.8 lg/mL, respectively.
Treatments and follow-up
Randomization was performed using a random number chart, and allocation to treatment groups was concealed until the patients had been randomized. Patients were randomly allocated to receive either 10-day sequential therapy [rabeprazole (20 mg daily) plus amoxicillin (1 g twice daily) for the first 5 days, followed by rabeprazole (20 mg), clarithromycin (500 mg) and tinidazole (500 mg) twice daily for the remaining 5 days] or standard 7-day therapy [rabeprazole (20 mg), clarithromycin (500 mg) and amoxicillin (1 g) twice daily].
Patients were also asked to return at the end of antibiotic treatment for a physical evaluation, to assess compliance with therapy and to determine side-effects.
Compliance was defined as consumption of > 90% of the prescribed drugs and was determined by pill counts at the follow-up visit. At a minimum of 6 weeks after the end of eradication therapy, endoscopy was repeated, with biopsies performed as at the baseline visit. Within 24 h of the second endoscopy, all patients also underwent a 13 C-urea breath test using the same methodology as at baseline.
Statistical analysis
The differences between the proportions of patients with successful eradication and their 95% confidence intervals for the two treatments were calculated using the method recommended by Newcombe and Altman, 21 and the level of significance was assessed using Fisher's exact test. As calculated by the statistical program (Intercooled STATA 6 for Windows 95/98/NT, USA), the sample size was chosen to detect a difference of 9% in the eradication rate between the standard 7-day (assumed to have an eradication rate of 80%) and the new 10-day (estimated to have an eradication rate of 89%) regimen, with a power of 0.90 and a significance level of 0.01 (a ¼ 0.010, two-sided). For this purpose, at least 501 patients had to be enrolled in each arm. For all other variables, chi-squared and t-test were used as appropriate, and P values less than 0.05 were considered to be significant. All patients randomized were included in the intention-to-treat analysis. Patients were not incorporated into the per protocol analysis when they consumed less than 50% of the prescribed drugs or when they did not complete follow-up. The difference between the proportions of patients with successful eradication using the two treatments (intention-to-treat and per protocol analysis) was estimated for each centre. Before pooling the estimates, a chisquared test was applied to investigate the heterogeneity between the differences. These criteria were determined before commencement of the study.
RESULTS
Eradication rates
One thousand and forty-nine patients fulfilled the entry criteria. The mean age ± s.d. was 53 ± 13 years and there were 545 men and 504 women. The characteristics of the intention-to-treat population are shown in Table 1 . Of these 1049 randomized patients, 16 (four male, 12 female; mean age, 52 ± 14 years) in the study group and 20 (12 male, eight female; mean age, 47 ± 11 years) in the control group were not available for the follow-up examination. Therefore, the study population available for per protocol analysis consisted of 1013 patients. Chi-squared tests to investigate the heterogeneity between the differences in the proportions of patients with successful eradication (for both intention-to-treat and per protocol analysis) using the two treatments, estimated for each centre, were not significant (P > 0.05). Moreover, the proportions of patients with successful eradication did not differ between centres for the new and standard treatment. The overall eradication rates of the two treatments by intentionto-treat and per protocol analysis are shown in Table 2 .
The eradication rate achieved with the new regimen was significantly higher than that obtained with the standard treatment, both in the intention-to-treat (92% vs. 74%; P < 0.0001) and per protocol (95% vs. 77%; P < 0.0001) analysis. The new treatment was also significantly more effective than standard therapy in patients with peptic ulcer disease (intention-to-treat, 97% vs. 75%; P < 0.0001; per protocol, 92% vs. 74%; P < 0.0001) and non-ulcer dyspepsia (intention--to-treat, 91% vs. 73%; P < 0.0001; per protocol, 94% vs. 77%; P < 0.0001). The eradication rates achieved with the new and standard treatment according to intention-to-treat analysis, for each centre, are shown in Table 3 , and the overall result is provided in Figure 1 . Culture was performed in 152 patients given the new treatment and in 154 patients given the standard regimen. Bacterial culture was successful in 135 of 152 (88.8%) and in 137 of 154 (89%) patients allocated to the new treatment and to the standard regimen, respectively. In sequential therapy, the prevalence of primary bacterial resistance to clarithromycin and nitroimidazole was 6.7% (95% CI, 3.5-12.2) and 26.7% (95% CI, 19.9-34.7), respectively. In standard therapy, the prevalence of strains resistant to clarithromycin and nitroimidazole was 4.4% (95% CI, 2-9.2) and 27% (95% CI, 20.3-35), respectively, with no significant difference between the two treatment groups (P ¼ 0.4 for clarithromycin; P ¼ 1 for nitroimidazole). No bacterial resistance to amoxicillin was observed. The eradication of H. pylori was significantly greater with the new regimen than with the standard treatment in patients with isolates resistant to clarithromycin (78% vs. 17%; difference for 10 days vs. 7 days, 61.1%; 95% CI, 9.8-82.1; P ¼ 0.04) or to Table 2 ).
Compliance and side-effects
Overall, 456 patients (90%) randomized to the new treatment and 471 (93%) assigned to standard therapy were compliant with the medication, and there was no significant difference between the two groups (P ¼ 0.11). A total of 50 patients allocated to the new regimen (47 patients presenting with non-ulcer dyspepsia and three presenting with peptic ulcer disease) and 36 patients (all presenting with non-ulcer dyspepsia) allocated to standard treatment consumed more than 50%, but less than 90%, of the prescribed pills. Both treatments were well tolerated. One patient randomized to the standard regimen stopped treatment because of severe diarrhoea. Thus, 36 and 45 patients (7% vs. 9%; P ¼ 0.3) allocated to the new and standard regimen, respectively, complained of minor side-effects (Table 4) . The most frequent side-effects in the two treatment arms were diarrhoea (39% vs. 35%, P ¼ 0.8, for the new regimen and standard therapy, respectively) and abdominal pain (22% vs. 29%, P ¼ 0.4, for the new regimen and standard therapy, respectively). Table 3 . Eradication results for the two regimens calculated by intention-to-treat analysis according to centre Sequential regimen (n ¼ 522) Standard regimen (n ¼ 527) Figure 1 . Flow chart representing the eradication rates after the new 10-day sequential treatment and standard 7-day triple therapy. * Including the patient who experienced severe diarrhoea and was withdrawn from the study.
DISCUSSION
We performed a large, multi-centre study to compare the efficacy of a novel sequential antibiotic treatment with that of standard therapy for H. pylori eradication. Our data confirm the finding of disappointing eradication rates after standard triple therapy, as widely reported in several recent studies. [5] [6] [7] [8] [9] [10] [11] 22 Indeed, one of every six patients with peptic ulcer disease remained infected after standard therapy. This could increase the risk of complications and costs. 23 In contrast, we found a high H. pylori eradication rate using the sequential regimen. It was significantly greater than that of standard triple therapy. Moreover, the sequential treatment showed high efficacy (> 90%) in patients with peptic ulcer disease and non-ulcer dyspepsia. The reason why sequential therapy is so effective is unclear, although certain hypotheses may be proposed. One possibility is that sequential treatments may exploit the advantages of both regimens. It is well known that short-term (< 7 days) treatment with a proton pump inhibitor and amoxicillin can eradicate H. pylori in up to 50% of infected patients, and reduces the bacterial load in the remaining cases. 24 The reduction of the bacterial load may improve the response to the subsequent short course of triple therapy. Indeed, some studies have shown that a low bacterial load is associated with a higher eradication rate after triple therapy. 25, 26 Amoxicillin was chosen in the initial dual therapy phase because resistance to this antimicrobial is extremely rare, and it has been found that regimens containing amoxicillin may prevent the selection of secondary clarithromycin resistance. 27 During the second phase, clarithromycin and tinidazole were chosen in order to exploit the efficacy of three different antibiotics. On the other hand, the simultaneous administration of antibiotics in a quadruple regimen (proton pump inhibitor, tetracycline, metronidazole and bismuth salts) has been shown to be effective in some studies, with an eradication rate in the range 90-100%, but other studies have shown a much lower eradication rate (60-84%) in patients with peptic ulcer disease, even when the treatment was administered for 12-14 days. [28] [29] [30] [31] [32] [33] [34] A large number of tablets have to be taken with quadruple regimens, and this may reduce patient compliance. 35 Bismuth toxicity may also be a cause for concern, as a recent study has found that 9% of patients receiving the quadruple regimen had very high blood bismuth concentrations. 36 Quadruple therapy is therefore generally considered as second-line therapy. 37 The prevalence of H. pylori strains resistant to antimicrobial agents is increasing in the USA and Europe, further reducing the efficacy of current regimens. 11, 14 Recent studies from Italy have reported clarithromycin resistance in 11-17% of subjects and metronidazole resistance in 17-44% of subjects. 5, [38] [39] [40] This is a substantial increase compared with data reported a few years ago, when the prevalence of clarithromycin resistance was 3.2% and the prevalence of metronidazole resistance was 15%. 41, 42 In the present study, resistance to clarithromycin and metronidazole was seen in 5.5% and 26.8% of subjects, respectively, at one centre, in agreement with data reported in other Italian studies. [38] [39] [40] This study was not designed to evaluate the two treatments in patients with resistant strains of H. pylori. Nevertheless, the sequential treatment was much more effective than standard triple therapy in eradicating strains resistant to either clarithromycin (77.8% vs. 16.7%) or metronidazole (94.4% vs. 70.3%). These values should, however, be interpreted with caution as culture was not performed in all cases, and the sample was small with wide confidence intervals. Although we have no data on the re-treatment of patients who failed to show H. pylori eradication with the new therapy, the sequential regimen included the same antibiotics as used in standard 7-day therapy, and therefore such patients could be managed using: (i) standard 7-day quadruple therapy; 2 (ii) 14-day ranitidine bismuthbased triple therapy; 43 (iii) a rifabutin-amoxicillin regimen; or (iv) a levofloxacin-amoxicillin combination. [44] [45] [46] It could be argued that we should have included, as a control group, a 10-day regimen instead of a standard 7-day treatment. However, the standard 7-day treatment is the regimen recommended by the European Helicobacter pylori Study Group in its recent guidelines as first-line treatment. 2 It is unlikely that the longer duration of therapy with our new regimen explains its greater efficacy. Indeed, a recent meta-analysis has clearly shown that 10-day therapy does not offer any significant advantage over 7-day therapy in terms of the H. pylori eradication rate. 12 The limitations of our study are that it was not blind and culture was not possible at all institutions. Unfortunately, culture and antimicrobial sensitivity testing require time, a dedicated microbiologist and financial resources. Most of these facilities were not available at each centre.
In conclusion, to our knowledge, this is the first large, multi-centre study of a therapeutic regimen superior to standard triple therapy. Further studies of primary resistance data are necessary in order to confirm the high eradication rates of this new treatment, and to explore the opportunity for the replacement of current triple therapies.
